Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
US Department of Justice
Cantor Fitzgerald
Argus Health
Harvard Business School
Teva
Dow
Medtronic
Express Scripts

Generated: July 19, 2018

DrugPatentWatch Database Preview

SERENTIL Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Serentil, and what generic alternatives are available?

Serentil is a drug marketed by Novartis and is included in three NDAs.

The generic ingredient in SERENTIL is mesoridazine besylate. There are two drug master file entries for this compound. Additional details are available on the mesoridazine besylate profile page.
Summary for SERENTIL
Drug patent expirations by year for SERENTIL
Medical Subject Heading (MeSH) Categories for SERENTIL
Synonyms for SERENTIL
(+-)-10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine monobenzenesulfonate
10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine monobenzenesulfonate
10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfinyl-phenothiazine
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfinyl)-10H-phenothiazine benzenesulfonate
10H-Phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-, (+-)-, monobenzenesulfonate
10H-Phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-, monobenzenesulfonate
2-METHANESULFINYL-10-[2-(1-METHYLPIPERIDIN-2-YL)ETHYL]-10H-PHENOTHIAZINE; BENZENESULFONIC ACID
2538AH
32672-69-8
AC1L1VB9
Benzenesulfonic acid, compd. with 10-(2-(1-methyl-2-piperidinyl)ethyl)- 2-(methylsulfinyl)ethyl)-10H-phenothiazine (1:1)
benzenesulfonic acid; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine
benzenesulfonic acid;10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine
C21H26N2OS2.C6H6O3S
CCG-100781
CCG-213471
CHEBI:6781
CHEMBL1201052
CPD000466274
CTK8G0808
D00795
HMS1569J19
HMS2051M09
HMS2096J19
HMS2234G16
HMS3369O09
HMS3393M09
J-018829
LS-32028
Mesoridazine benzenesulfonate
Mesoridazine benzenesulfonate, >=98% (HPLC), powder
mesoridazine besilate
Mesoridazine Besilate (10-[2-[(2RS)-1-Methylpiperidin-2-yl]ethyl]-2-(methylsufhinyl)-10H-phenothiazine Besilate)
MESORIDAZINE BESYLATE
Mesoridazine besylate (USP)
Mesoridazine besylate [USAN]
Mesoridazine besylate [USP]
Mesoridazine besylate, United States Pharmacopeia (USP) Reference Standard
mesoridazine monobenzenesulfonate
MFCD00800983
MLS000758302
MLS001424031
MLS002222270
MolPort-035-395-825
NC 123
NC00031
NSC-760073
NSC760073
Pharmakon1600-01505500
PL054141
Prestwick_853
Prestwick0_000529
SAM001247051
SCHEMBL41229
Serentil (TN)
SMR000449304
SMR000466274
thioridazine-2-sulfoxide besylate

US Patents and Regulatory Information for SERENTIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis SERENTIL mesoridazine besylate CONCENTRATE;ORAL 016997-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis SERENTIL mesoridazine besylate TABLET;ORAL 016774-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis SERENTIL mesoridazine besylate INJECTABLE;INJECTION 016775-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis SERENTIL mesoridazine besylate TABLET;ORAL 016774-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Army
McKesson
Mallinckrodt
Teva
Accenture
Medtronic
QuintilesIMS
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.